CD274 and viral infectious disease: The combination of anti-PD-L1 monoclonal antibodies, a nucleoside analogue, and a therapeutic DNA vaccine led to viral replication suppression and seroconversion in a woodchuck model, obtaining a sustained immunological control of viral infection due to potently enhanced HBV-specific T-cell function, but not with anti-PD-L1 monoclonal antibodies alone [68].